AUC/MIC-Guided Vancomycin Dosing in Patients With MRSA Bacteremia Results in Decreased Troughs
MAY 10, 2019 | ALEXANDRA WARD
Vancomycin dosing has remained a controversial topic in the management of infectious diseases as many medical centers move away from trough-guided and toward area under the curve/minimum inhibitory concentration (AUC/MIC)-guided dosing.
Investigators at Boston Medical Center, a large academic facility, implemented a change to their primary targets for vancomycin dosing in January 2018 for patients with methicillin-resistant Staphylococcus aureus (MRSA) blood stream infections (BSI). The goal was to move from troughs to AUC/MIC to reduce the cumulative exposure of vancomycin by 10% and decrease average troughs by 20%.
Matthew Girgis, PharmD, PGY-2 Pharmacy Resident at Boston Medical Center and an investigator on the study, shared the outcomes at the 22nd annual Making a Difference in Infectious Diseases (MAD-ID 2019) meeting (see video).
The study, part of a quality improvement project rolled out in plan-do-study-act (PDSA) cycles, included a baseline group of patients with MRSA BSI who had been admitted to Boston Medical Center between January and December 2017 and received at least 4 doses of vancomycin. Troughs of 15 to 20 mcg/mL were the primary target. PDSA cycle 1 included patients with MRSA BSI admitted from January to September 2018 and dosed via AUC/MIC. PDSA cycle 2 included patients with MRSA BSI admitted from October to December 2018, dosed via AUC/MIC, and who received empiric dosing and had modifications to documentation requirements.
In the baseline group of 37 patients, the average daily vancomycin dose was 2.9 g and the average trough was 16 mcg/mL (19% supratherapeutic). The incidence of vancomycin-induced nephrotoxicity (VIN) was 8%. In the 36 patients in PDSA cycle 1, the average daily vancomycin dose was 2.5 g and the average trough was 14 mcg/mL (9% supratherapeutic). The incidence of VIN was 19%. In the 13 patients included in PDSA cycle 2, the average daily vancomycin dose was 2.1 g and the average trough was 13.2 mcg/mL (8% supratherapeutic). The VIN incidence was 15%.
Investigators concluded that in patients with MRSA bacteremia, implementing AUC/MIC-guided vancomycin dosing resulted in decreased average troughs and a decrease in daily vancomycin dose administered.
“The increased rate of acute kidney injury seen in the AUC group occurred in the setting of more frequent co-administration of nephrotoxic medications and was not thought to be related to the vancomycin dosing,” the investigators wrote.
The study, “Hospital Wide Implementation of Vancomycin Area Under the Curve/Minimum Inhibitory Concentration (AUC/MIC) Dosing at a Large Academic Medical Center,” was presented at MAD-ID 2019, held May 8-11, 2019, in Orlando, Florida.
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Big advances in treatment can't make up for an inability to stop new infections, which number 5,000 per day worldwide.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512